Negative Trials Fail to Dampen Enthusiasm for Adjuvant, Combination Therapy in RCC
October 10th 2022Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.
Frontline Immunotherapy Combos Linked With Higher CR Rates Than Anti-VEGF Therapy in mRCC
September 20th 2022Immunotherapy-based combinations elicited higher complete response rates compared with VEGF-targeted therapy when used as first-line treatment in patients with metastatic renal cell carcinoma.
HRQOL Is Maintained With Nivolumab in Real-World Population of Pretreated mRCC
September 20th 2022Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.
HRQoL Proves to Be Helpful Prognostic Factor for Cabozantinib/Nivolumab in Advanced RCC
September 14th 2022Higher baseline and longitudinal evaluations of health-related quality of life prior to and during treatment with nivolumab and cabozantinib demonstrated an association with improved progression-free survival and overall survival in patients with advanced, treatment-naïve renal cell carcinoma.
Increased In-Situ and Immune Expression Enrich for Nivolumab/Ipilimumab Efficacy in Metastatic RCC
September 12th 2022The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was shown to be associated with an increased response rate and prolonged progression-free survival with the combination of nivolumab and ipilimumab as frontline therapy in patients with metastatic renal cell carcinoma.
Cabozantinib Improves PFS Outcomes With Nivolumab, Ipilimumab in Advanced RCC
September 12th 2022The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.
Nivolumab/Ipilimumab Boosting Following Nivolumab Monotherapy Increases Responses in Advanced RCC
September 11th 2022A tailored approach utilizing the combination of nivolumab and ipilimumab as an immunotherapeutic boost following induction with single-agent nivolumab improved responses in the first and second line for patients with advanced renal cell carcinoma.
Lenvatinib/Pembrolizumab Combo Provides Continued OS, PFS Benefit in Advanced RCC
September 11th 2022Lenvatinib plus pembrolizumab showed sustained overall survival and progression-free survival benefit across poor- and intermediate-risk subgroups of patients with advanced renal cell carcinoma.